Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
01/03/2016
Completion of enrolment according to the study protocol for the phase I part of the VB C-01 study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
01/02/2016
Vaccibody awarded NOK 20 million (USD 2.3 million) to develop patient-specific therapeutic cancer vaccines
14/09/2015
Vaccibody AS announces vaccination of first patient in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
12/08/2015
Vaccibody AS announces approval to initiate its first clinical trial
30/06/2015
VACCIBODY APPOINTS MARTIN BONDE AS CEO
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer